Stana Moisescu is the new CEO of Teva Pharmaceuticals Romania

Aurel Dragan 23/07/2018 | 16:04

Teva Pharmaceuticals, global leader in the production of generic drugs, announces the appointment of Stana Moisescu as general director of its branch in Romania. The company is operating in Romania since 2006 and delivers drugs and healthcare solutions. Globally, Teva ranks first position in the top of the generic drugs companies, with operations in 60 countries and a portfolio of over 1,800 molecules.

„I am honored and in the same time it is a challenge for me to take over the management of Teva Pharmaceuticals in Romania. I am in this company for eight years already and along with the team we contributed to its progress. I will continue to be a team player and I am thrilled to have the privilege of working with professionals, with a good knowledge of the pharmaceutical industry. Our priority in terms of business is to consolidate our position of important supplier of quality drugs for the Romanian patients”, said Stana Moisescu, the new CEO of Teva Pharmanceuticals Romania.

Stana Moisescu has been since 2010 one of the key-member of the company. Before joining Teva, Stana was Financial Director at Ness Romania, an IT company. Prior to this, Stana Moisescu worked at GlaxoSmithKline for 12 years, where she had several positions, among them Financial Director and Chief Accountant.

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva’s net revenues in 2017 were USD 22.4 billion.

BR Magazine | Latest Issue

Download PDF: Business Review Magazine March (II) 2024 Issue

The March (II) 2024 issue of Business Review Magazine is now available in digital format, featuring the main cover story titled “BAT DBS Romania Hub: A Vibrant New Office For An Employee-Centric
Aurel Dragan | 27/03/2024 | 17:32
Advertisement Advertisement
Close ×

We use cookies for keeping our website reliable and secure, personalising content and ads, providing social media features and to analyse how our website is used.

Accept & continue